SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Raynor MC, Carson CC, Pearson MD, Nix JW. Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy. Can J Urol 2007; 14: 638
  • 2
    American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract 2002; 8: 43956
  • 3
    Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 19952010
  • 4
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 72431
  • 5
    Population Division US Census Bureau. Projections of the Population by Selected Age Groups and Sex for the United States: 2010–2050 , 2008. Available at: http://www.census.gov/population/www/projections/files/nation/summary/np2008-t2.xls. Accessed August 2008
  • 6
    Araujo AB, O’Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 59206
  • 7
    Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22: 71831
  • 8
    Muller M, Van Der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease. J Clin Endocrinol Metab 2003; 88: 507686
  • 9
    Kupelian V, Page ST, Araujo AB et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 84350
  • 10
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 248697
  • 11
    Laaksonen DE, Niskanen L, Punnonen K et al. Sex hormone, inflammation, and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 6018
  • 12
    Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 82734
  • 13
    Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 48292
  • 14
    Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol 2001; 54: 43745
  • 15
    Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994; 40: 3419
  • 16
    Bhasin S, Singh AB, MacRP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299311
  • 17
    Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006; 18: 2015
  • 18
    Wang C, Cunningham G, Dobs A et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 208598
  • 19
    Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96: 67M72M
  • 20
    Svatek RS, Shulman MJ, Benaim EA, Rogers TE, Margulis V. Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. J Urol 2008; 179: 21926
  • 21
    Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 9359